Table 2.
Marker | Cut-off | Low group | High group | Log-rank P value | Direction of HR: high/low | ||||
---|---|---|---|---|---|---|---|---|---|
Quantile | Value | n | MST | n | MST | With FDR | HR (95% CI) | ||
Association with PFS | |||||||||
ANG-2 | 0.5 | 6.800 μg/L | 27 | 20.1 | 21 | 5.9 | 0.0351 | 0.1508 | 2.360 (1.040–5.355) |
HGF | 0.5 | 7.350 μg/L | 28 | 20.1 | 20 | 5.6 | 0.0264 | 0.1508 | 2.550 (1.088–5.974) |
IL-18 | 0.5 | 264.0 ng/L | 28 | 14.7 | 20 | 5.6 | 0.0317 | 0.1508 | 2.418 (1.058–5.526) |
IL-18BP | 0.5 | 17.0 μg/L | 24 | 17.5 | 24 | 6.9 | 0.0305 | 0.1508 | 2.431 (1.059–5.580) |
M-CSF | 0.5 | 0.9650 μg/L | 28 | 14.7 | 20 | 7.4 | 0.1144 | 0.3088 | 1.904 (0.845–4.288) |
MIG | 0.5 | 1250 ng/L | 30 | 20.1 | 18 | 7.4 | 0.0299 | 0.1508 | 2.506 (1.062–5.914) |
TIMP-1 | 0.5 | 199.0 μg/L | 26 | 14.7 | 22 | 5.6 | 0.0392 | 0.1508 | 2.326 (1.023–5.291) |
VEGF | 0.5 | 305.0 ng/L | 29 | 14.7 | 19 | 11.2 | 0.2526 | 0.5247 | 1.597 (0.711–3.587) |
Association with OS | |||||||||
ANG-2 | 0.5 | 6.800 μg/L | 27 | NE | 21 | 21.7 | 0.003 | 0.0137 | 3.005 (1.402–6.442) |
HGF | 0.5 | 7.350 μg/L | 28 | 32.2 | 20 | 20.5 | 0.0081 | 0.0258 | 2.592 (1.249–5.377) |
IL-18 | 0.5 | 264.0 ng/L | 28 | 32.1 | 20 | 20.7 | 0.0163 | 0.0367 | 2.376 (1.149–4.915) |
IL-18BP | 0.5 | 17.00 μg/L | 24 | 32.2 | 24 | 18.4 | 0.0008 | 0.0073 | 3.469 (1.605–7.501) |
M-CSF | 0.5 | 0.9650 μg/L | 28 | NE | 20 | 14.5 | 0.0002 | 0.0044 | 3.765 (1.781–7.959) |
MIG | 0.5 | 1250 ng/L | 30 | 25.5 | 18 | 25.5 | 0.9668 | 0.9668 | 0.985 (0.472–2.056) |
TIMP-1 | 0.5 | 199.0 μg/L | 26 | NE | 22 | 16.1 | 0.0003 | 0.0044 | 3.770 (1.741–8.162) |
VEGF | 0.5 | 305.0 ng/L | 29 | 32.2 | 19 | 20.5 | 0.0021 | 0.0137 | 2.993 (1.441–6.213) |
Biomarkers most strongly associated with PFS or OS (by HR), respectively, are shaded grey.
ANG-2 angiopoietin-2, FDR false discovery rate, HGF hepatocyte growth factor, HR hazard ratio, IL-18 interleukin-18, IL-18BP interleukin-18 binding protein, M-CSF macrophage colony-stimulating factor, MIG monokine induced by gamma interferon, MST median survival time, NE not estimable, OS overall survival, PFS progression-free survival, TIMP-1 tissue inhibitor of metalloproteinase-1, VEGF vascular endothelial growth factor.